Breaking News

GSK Discontinues Development of Anacor Drug

October 5, 2012

Returns all rights, amends R&D pact

GlaxoSmithKline has discontinued development of GSK2251052 following a recent clinical trial that was stopped due to the identification of microbiological findings of resistance in a small number of patients undergoing treatment of complicated urinary tract infections (cUTI). GSK has decided to discontinue further development of GSK2251052 and return all rights to Anacor.
 
Anacor Pharmaceuticals licensed the drug to GSK in July 2010 under an ongoing R&D collaboration. GSK is continuing to fund Anacor’s research activities in tuberculosis as under the companies’ amended R&D collaboration.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers